Proteomics of the Dystrophin-glycoprotein Complex and Dystrophinopathy

Current Protein and Peptide Science

Volumn 14, Issue 8, 2013, Pages 680-697

  Holland, Ashling ^a   Carberry, Steven ^a   Ohlendieck, Kay ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Dystrobrevin; Dystroglycan; Dystrophin; Dystrophin glycoprotein complex; Muscular dystrophy; Sarcoglycan; Sarcospan; Syntrophin

Indexed keywords

ACTIN BINDING PROTEIN; ALPHA DYSTROGLYCAN; ALPHA SARCOGLYCAN; BETA DYSTROGLYCAN; BETA SARCOGLYCAN; DYSTROPHIN; DYSTROPHIN ASSOCIATED PROTEIN; GAMMA SARCOGLYCAN; GLYCOPROTEIN; LAMININ; UTROPHIN;

AFFINITY CHROMATOGRAPHY; DOWN REGULATION; DYSTROPHINOPATHY; HISTOLOGY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; ION EXCHANGE CHROMATOGRAPHY; MASS SPECTROMETRY; NEUROMUSCULAR SYNAPSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; REVIEW; SARCOLEMMA; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; DYSTROPHIN; GLYCOPROTEINS; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; PROTEOMICS;

EID: 84891805627     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113146660083     Document Type: Review

References (231)

1. Labeit, S.; Kolmerer, B. Titins: giant proteins in charge of muscle ultrastructure and elasticity. Science, 1995, 270, 293-296.
2. Tennyson, C.N.; Klamut, H.J.; Worton, R.G. The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. Nat. Genet., 1995, 9, 184-190.
3. Hoffman, E.P.; Brown, R.H. Jr; Kunkel, L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 1987, 51, 919-928.
4. Ohlendieck, K.; Ervasti, J.M.; Matsumura, K.; Kahl, S.D.; Leveille, C.J.; Campbell, K.P. Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. Neuron, 1991, 7, 499-508.
5. Campbell, K.P.; Kahl, S.D. Association of dystrophin and an integral membrane glycoprotein. Nature, 1989, 338, 259-262.
6. Matsumura, K.; Ervasti, J.M.; Ohlendieck, K.; Kahl, S.D.; Campbell K.P. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature, 1992, 360, 588-591.
7. Ohlendieck, K. Skeletal muscle proteomics: current approaches, technical challenges and emerging techniques. Skelet. Muscle, 2011, 1 (1), 6.
8. Koenig, M.; Hoffman, E.P.; Bertelson, C.J.; Monaco, A.P.; Feener, C.; Kunkel, L.M.; Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 1987, 50, 509-517.
9. Koenig, M.; Monaco, A.P.; Kunkel, L.M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell, 1988, 53, 219-228.
10. Ervasti, J.M.; Ohlendieck, K.; Kahl, S.D.; Gaver, M.G.; Campbell, K.P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature, 1990, 345, 315-319.
11. Yoshida, M.; Ozawa, E. Glycoprotein complex anchoring dystrophin to sarcolemma. J. Biochem., 1990, 108, 748-752.
12. Koenig, M.; Beggs, A.H.; Moyer, M.; Scherpf, S.; Heindrich, K.; Bettecken, T.; Meng, G.; Müller, C.R.; Lindlöf, M.; Kaariainen, H.; de la Chapelle, A.; Kiuru, A.; Savontaus, M.-L.; Gilgenkrantz, H.; Récan, D.; Chelly, J.; Kaplan, J.-C.; Covone, A.E.; Archidiacono, N.; Romeo, G.; Liechti-Gallati, S.; Schneider, V.; Braga, S.; Moser, H.; Darras, B.T.; Murphy, P.; Francke, U.; Chen, J.D.; Morgan, G.; Denton, M.; Greenberg, C.R.; Wrogemann, K.; Blonden, L.A.J.; van Paassen, H.M.B.; van Ommen, G.J.B.; Kunkel, L.M. The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. Am. J. Hum. Genet., 1989, 45, 498-506.
13. Bradley, W.G.; Hudgson, P.; Larson, P.F.; Papapetropoulos, T.A.; Jenkison, M. Structural changes in the early stages of Duchenne muscular dystrophy. J. Neurol. Neurosurg. Psychiatry., 1972, 35, 451-455.
14. Nigro, G.; Comi, L.I.; Politano, L.; Bain, R.J. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol., 1990, 26, 271-277.
15. Fayssoil, A.; Nardi, O.; Orlikowski, D.; Annane, D. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. Heart Fail. Rev., 2010, 15, 103-107.
16. Kozicka, A.; Prot, J.; Wasilewski, R. Mental retardation in patients with Duchenne progressive muscular dystrophy. J. Neurol. Sci., 1971, 14, 209-213.
17. Pane, M.; Lombardo, M.E.; Alfieri, P.; D'Amico, A.; Bianco, F.; Vasco, G.; Piccini, G.; Mallardi, M.; Romeo, D.M.; Ricotti, V.; Ferlini, A.; Gualandi. F.; Vicari, S.; Bertini, E.; Berardinelli, A.; Mercuri, E. Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. J. Pediatr., 2012, 161, 705-709.
18. Bushby, K.; Finkel, R.; Birnkrant, D.J.; Case, L.E.; Clemens, P.R.; Cripe, L.; Kaul, A.; Kinnett, K.; McDonald, C.; Pandya, S.; Poysky, J.; Shapiro, F.; Tomezsko, J.; Constantin, C. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol., 2010, 9, 77-93.
19. Bushby, K.; Finkel, R.; Birnkrant, D.J.; Case, L.E.; Clemens, P.R.; Cripe, L.; Kaul, A.; Kinnett, K.; McDonald, C.; Pandya, S.; Poysky, J.; Shapiro, F.; Tomezsko, J.; Constantin, C. DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol., 2010, 9, 177-189.
20. Zubrzycka-Gaarn, E.E.; Bulman, D.E.; Karpati, G.; Burghes, A.H.; Belfall, B.; Klamut, H. J; Talbot, J.; Hodges, R.S.; Ray, P.N.; Worton, R.G. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature, 1988, 333, 466-469.
21. Ohlendieck, K. Characterisation of the dystrophin-related protein utrophin in highly purified skeletal muscle sarcolemma vesicles. Biochim. Biophys. Acta., 1996, 1283, 215-222.
22. Young, H.S.; Herbette, L.G.; Skita, V. β-Bungarotoxin Binding to Acetylcholine Receptor Membranes Studied by Low Angle X-Ray Diffraction. Biophys. J., 2003, 85, 943-953.
23. Thanh, L.T.; Nguyen, T.M.; Helliwell, T.R.; Morris, G.E. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am. J. Hum. Genet., 1995, 56, 725-731.
24. Zellweger, H.; Antonik, A. Newborn screening for Duchenne muscular dystrophy. Pediatrics, 1975, 55, 30-34.
25. Hoffman, E.P.; Fischbeck, K.H.; Brown, R.H.; Johnson, M.; Medori, R.; Loike, J.D.; Harris, J.B.; Waterston, R.; Brooke, M.; Specht, L.; Kupsky, W.; Chamberlain, J.; Caskey, C.T.; Shapiro, F.; Kunkel, L.M. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N. Engl. J. Med., 1988, 318, 1363-1368.
26. Campbell, K.P. Three muscular dystrophies: loss of cytoskeletonextracellular matrix linkage. Cell, 1995, 80, 675-679.
27. Dalkilic, I.; Kunkel, L.M. Muscular dystrophies: genes to pathogenesis. Curr. Opin. Genet. Dev., 2003, 13, 231-238.
28. Muntoni, F.; Torelli, S.; Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol., 2003, 2, 731-740.
29. Broderick, M.J.; Winder, S.J. Spectrin, alpha-actinin, and dystrophin. Adv. Protein Chem., 2005, 70, 203-246.
30. Djinovic-Carugo, K.; Gautel, M.; Ylänne, J.; Young, P. The spectrin repeat: a structural platform for cytoskeletal protein assemblies. FEBS Lett., 2002, 513, 119-23.
31. Roberts, R.G.; Coffey, A.J.; Bobrow, M.; Bentley, D.R. Exon structure of the human dystrophin gene. Genomics, 1993, 16, 536-538.
32. Sadoulet-Puccio, H.M.; Kunkel, L.M. Dystrophin and its isoforms. Brain Pathol., 1996, 6, 25-35.
33. Tuzun, E.; Sharp, A.J.; Bailey, J.A.; Kaul, R.; Morrison, V.A.; Pertz, L.M.; Haugen, E.; Hayden, H.; Albertson, D.; Pinkel, D.; Olson, M.V.; Eichler, E.E. Fine-scale structural variation of the human genome. Nat. Genet., 2005, 37, 727-732.
34. Klamut, H.J.; Gangopadhyay, S.B.; Worton, R.N.; Ray, P.N. Molecular and functional analysis of the muscle-specific promoter region of the Duchenne muscular dystrophy gene. Mol. Cell. Biol., 1990, 10, 193-205.
35. Nudel, U.; Zuk, D.; Einat, P.; Zeelon, E.; Levy, Z.; Neuman, S.; Yaffe, D. Duchenne muscular dystrophy gene product is not identical in muscle and brain. Nature, 1989, 337, 76-78.
36. Gorecki, D.C.; Monaco, A.P.; Derry, J.M.J.; Walker, A.P.; Barnard, E.A.; Barnard, P.J. Expression of four alternative transcripts in human brain regions regulated by different promoters. Hum. Mol. Genet., 1992, 1, 505-510.
37. D'Souza, V.N.; Nguyen, T. M; Morris, G.E.; Karges, W.; Pillers, D.A.; Ray, P.N. A novel dystrophin isoform is required for normal retinal electrophysiology. Hum. Mol. Genet., 1995, 4, 837-842.
38. Lidov, H.G.W.; Selig, S.; Kunkel, L.M. Dp140: a novel 140 kDa cns transcript from the dystrophin locus. Hum. Mol. Genet., 1995, 4, 329-335.
39. Byers, T.J.; Lidov, H.G.W.; Kunkel, L.M. An alternative dystrophin transcript specific to peripheral nerve. Nature Genet., 1993, 4, 77-81.
40. Bar, S.; Barnea, E.; Lavy, Z.; Neuman, S.; Yaffe, D.; Nudel, U. A novel protein product of the Duchenne muscular dystrophy gene which greatly differs from known isoforms in its structure and tissue distribution. Biochem. J., 1990, 272, 557-560.
41. Tinsley, J.M.; Blake, D.J.; Davies, K.E. Apo-dystrophin 3: a 2. 2 kb transcript from the DMD locus encoding the dystrophin glycoprotein binding site. Hum. Mol. Genet., 1993, 2, 521-524.
42. Culligan, K.; Ohlendieck, K. Diversity of the Brain Dystrophin-Glycoprotein Complex. J. Biomed. Biotechnol., 2002, 2, 31-36.
43. Sadoulet-Puccio, H.M.; Feener, C.A.; Schaid, D.J.; Thibodeau, S.N.; Michels, V.V.; Kunkel, L.M. The genomic organization of human dystrobrevin. Neurogenetics, 1997, 1, 37-42.
44. Nakamori, M.; Takahashi, M.P. The role of alpha-dystrobrevin in striated muscle. Int. J. Mol. Sci., 2011, 12, 1660-1671.
45. Peters, M.F., O'Brien, K.F., Sadoulet-Puccio, H.M., Kunkel, L.M., Adams, M.E.; Froehner, S.C. MM-dystrobrevin, a new member of the dystrophin family. J. Biol. Chem., 1997, 272, 31561-31569.
46. Blake, D.J.; Nawrotzki, R.; Loh, N.Y.; Gorecki, D.C.; Davies, K.E. EE-dystrobrevin, a member of the dystrophin-related protein family. Proc. Natl. Acad. Sci. USA, 1998, 95, 241-246.
47. Love, D.R.; Hill, D.F.; Dickson, G.; Spurr, N.K.; Byth, B.C.; Marsden, R.F.; Walsh, F.S.; Edwards, Y.H.; Davies, K.E. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature, 1989, 339, 55-58.
48. Tinsley, J.M.; Blake, D.J.; Roche, A.; Fairbrother, U.; Riss, J.; Byth, B.C.; Knight, A.E.; Kendrick-Jones, J.; Suthers, G.K.; Love, D.R.; Edwards, Y.H.; Davies, K.E. Primary structure of dystrophin-related protein. Nature, 1992, 360, 591-593.
49. Roberts, R.G.; Freeman, T.C.; Kendall, E.; Vetrie, D.L.P.; Dixon, A.K.; Shaw-Smith, C.; Bone, Q.; Bobrow, M. Characterization of DRP2, a novel human dystrophin homologue. Nature Genet., 1996, 13, 223-226.
50. Nguyen, T.M.; Helliwell, T.R.; Simmons, C.; Winder, S.J.; Kendrick-Jones, J.; Davies, K.E.; Morris, C. Full-length and short forms of utrophin, the dystrophin-related protein. FEBS Lett., 1995, 258, 262-266.
51. Norwood, F.L.; Sutherland-Smith, A.J.; Keep, N.H.; Kendrick-Jones, J. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure, 2000, 8, 481-491.
52. Muthu, M.; Richardson, K.A.; Sutherland-Smith, A.J. The Crystal Structures of Dystrophin and Utrophin Spectrin Repeats: Implications for Domain Boundaries. PLoS ONE, 2012, 7 (7), e40066.
53. Hnia, K.; Zouiten, D.; Cantel, S.; Chazalette, D.; Hugon, G.; Fehrentz, J.A.; Masmoudi, A.; Diment, A.; Bramham, J.; Mornet, D.; Winder, S.J. ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site. Biochem. J., 2007, 401, 667-77.
54. Ilsley, J.L.; Sudol, M.; Winder, S.J. The interaction of dystrophin with beta-dystroglycan is regulated by tyrosine phosphorylation. Cell Signal., 2001, 13, 625-632.
55. Ilsley, J.L.; Sudol, M.; Winder, S.J. The WW domain: linking cell signalling to the membrane cytoskeleton. Cell Signal., 2002, 14, 183-189.
56. Sadoulet-Puccio, H.M.; Rajala, M.; Kunkel, L.M. Dystrobrevin and dystrophin: An interaction through coiled-coil motifs. Proc. Natl. Acad. Sci. USA, 1997, 94, 12413-12418.
57. Le Rumeur, E.; Winder, S.J.; Hubert, J.F. Dystrophin: more than just the sum of its parts. Biochim. Biophys. Acta., 2010, 1804, 1713-1722.
58. Partridge, T.A. Impending therapies for Duchenne muscular dystrophy. Curr. Opin. Neurol., 2011, 24, 415-422.
59. Ervasti, J.M.; Kahl, S.D.; Campbell, K.P. Purification of dystrophin from skeletal muscle. J. Biol. Chem., 1991, 266, 9161-9165.
60. Peri, V.; Ajdukovic, B.; Holland, P.; Tuana, B.S. Dystrophin predominantly localizes to the transverse tubule/Z-line regions of single ventricular myocytes and exhibits distinct associations with the membrane. Mol. Cell. Biochem., 1994, 130, 57-65.
61. Ohlendieck, K.; Ervasti, J.M.; Snook, J.B.; Campbell, K.P. Dystrophin-glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. J. Cell Biol., 1991, 112, 135-148.
62. Ohlendieck, K.; Campbell, K.P. Dystrophin constitutes 5% of membrane cytoskeleton in skeletal muscle. FEBS Lett., 1991, 283, 230-234.
63. Lewis, C.; Ohlendieck, K. Mass spectrometric identification of dystrophin isoform Dp427 by on-membrane digestion of sarcolemma from skeletal muscle. Anal. Biochem., 2010, 404, 197-203.
64. Mechref, Y.; Madera, M.; Novotny, M.V. Glycoprotein enrichment through lectin affinity techniques. Methods Mol. Biol., 2008, 424, 373-396.
65. Lotan, R.; Gussin, A. E; Lis, H.; Sharon, N. Purification of wheat germ agglutinin by affinity chromatography on a sepharose-bound N-acetylglucosamine derivative. Biochem. Biophys. Res. Commun., 1973, 52, 656-662.
66. Ohlendieck, K. Towards an understanding of the dystrophinglycoprotein complex: linkage between the extracellular matrix and the membrane cytoskeleton in muscle fibers. Eur. J. Cell Biol., 1996, 69, 1-10.
67. Watkins, S.C.; Hoffman, E.P.; Slayter, H.S.; Kunkel, L.M. Immunoelectron microscopic localization of dystrophin in myofibres. Nature, 1988, 333, 863-866.
68. Ervasti, J.M.; Campbell, K.P. A role for the dystrophinglycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol., 1993, 122, 809-823.
69. Rybakova, I.N.; Ervasti, J.M. Dystrophin-glycoprotein complex is monomeric and stabilizes actin filaments in vitro through lateral association. J. Biol. Chem., 1997, 272, 28771-28778.
70. Gee, S.H.; Gee, R.; Madhaven, S.H.; Levinson, S.R.; Caldwell, J.H.; Sealock, R.; Froehner, S.C. Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins. J. Neurosci., 1998, 18, 128-137.
71. Roberds, S.L.; Anderson, R.D.; Ibraghimov-Beskrovnaya, O.; Campbell, K.P. Primary structure and muscle-specific expression of the 50-kDa dystrophin-associated glycoprotein (adhalin). J. Biol. Chem., 1993, 268, 23739-23742.
72. Yoshida, M.; Noguchi, S.; Wakabayashi, E.; Piluso, G.; Belsito, A.; Nigro, V.; Ozawa, E. The fourth component of the sarcoglycan complex. FEBS Lett., 1997, 403, 143-148.
73. Anastasi, G.; Cutroneo, G.; Rizzo, G.; Favaloro, A. Sarcoglycan subcomplex in normal and pathological human muscle fibers. Eur. J. Histochem., 2007, 51 (Suppl 1), 29-33.
74. Groh, S.; Zong, H.; Goddeeris, M.M.; Lebakken, C.S.; Venzke, D.; Pessin, J.E.; Campbell, K.P. Sarcoglycan complex: implications for metabolic defects in muscular dystrophies. J. Biol. Chem., 2009, 284, 19178-19182.
75. Crosbie, R.H.; Lim, L.E.; Moore, S.A.; Hirano, M.; Hays, A.P.; Maybaum, S.W.; Collin, H.; Dovico, S.A.; Stolle, C.A.; Fardeau, M.; Tomé, F.M.; Campbell, K.P. Molecular and genetic characterization of sarcospan: insights into sarcoglycan-sarcospan interactions. Hum. Mol. Genet., 2000, 9, 2019-2027.
76. Ibraghimov-Beskrovnaya, O.; Ervasti, J.M.; Leveille, C.J.; Slaughter, C.A.; Sernett, S.W.; Campbell, K.P. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature, 1992, 355, 696-702.
77. Bozzi, M.; Morlacchi, S.; Bigotti, M.G.; Sciandra, F.; Brancaccio, A. Functional diversity of dystroglycan. Matrix Biol., 2009, 28, 179-187.
78. Moore, C.J.; Winder, S.J. The inside and out of dystroglycan posttranslational modification. Neuromuscul. Disord., 2012, 22, 959-965.
79. Brenman, J.E.; Chao, D.S.; Gee, S.H.; McGee, A.W.; Craven, S.E.; Santillano, D.R.; Wu, Z.; Huang, F.; Xia, H.; Peters, M.F.; Froehner, S.C.; Bredt, D.S. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and ww1-syntrophin mediated by PDZ domains. Cell, 1996, 84, 757-767.
80. Ervasti, J.M.; Sonnemann, K.J. Biology of the striated muscle dystrophin-glycoprotein complex. Int. Rev. Cytol., 2008, 265, 191-225.
81. Gumerson, J.D.; Michele, D.E. The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol., 2011, 2011, 210797.
82. Culligan, K.G.; Mackey, A.J.; Finn, D.M.; Maguire, P.B.; Ohlendieck, K. Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Int. J. Mol. Med., 1998, 2, 639-648.
83. Beggs, A.H.; Hoffman, E.P.; Snyder, J.R.; Arahata, K.; Specht, L.; Shapiro, F.; Angelini, C.; Sugita, H.; Kunkel, L.M. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am. J. Hum. Genet., 1991, 49, 54-67.
84. Mutoni, F.; Melis, M.A.; Ganau, A.; Dubowitz, V. Transcription of the dystrophin gene in normal tissues and in skeletal muscle of a family with X-linked dilated cardiomyopathy. Am. J. Hum. Genet., 1995, 56, 151-157.
85. Rocha, C.T.; Hoffman, E.P. Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies. Curr. Neurol. Neurosci. Rep., 2010, 10, 267-276.
86. Carmignac, V.; Durbeej, M. Cell-matrix interactions in muscle disease. J. Pathol., 2012, 226, 200-218.
87. Helbling-Leclerc, A.; Zhang, X.; Topaloglu, H.; Cruand, C.; Tesson, F.; Weissenbach, J.; Tome, F.M.S.; Schwartz, K. Fardeau, M.; Tryggvason, K.; Guicheney, P. Mutations in the laminin MM2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nature Genet., 1995, 11, 216-218.
88. Godfrey, C.; Foley, A.R.; Clement, E.; Muntoni, F. Dystroglycanopathies: coming into focus. Curr. Opin. Genet. Dev., 2011, 21, 278-285.
89. Hewitt, J.E. Abnormal glycosylation of dystroglycan in human genetic disease. Biochim. Biophys. Acta., 2009, 1792, 853-861.
90. Romero, N.B.; Tome, F.M.S.; Leturcq, F.; Kerch, F.E.; Azibi, K.; Bachner, L.; Anderson, R.D.; Roberds, S.L.; Campbell, K.P.; Fardeau, M.; Kaplan, J.C. Genetic heterogeneity of severe childhood autosomal recessive muscular dystrophy with adhalin (50 kDa dystrophin-associated glycoprotein) deficiency. CR Acad. Sci. (France), 1994, 317, 70-76.
91. Boennemann, C.G.; Modi, R.; Noguchi, S.; Mizuno, Y.; Yoshida, M.; Gussoni, E.; McNally, E.M.; Duggan, D.J.; Angelini, C.; Hoffman, E.P.; Ozawa, E.; Kunkel, L.M. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature Genet., 1995, 11, 266-272.
92. Noguchi, S.; McNally, E.M.; Othmane, K.B.; Hagiwara, Y.; Mizuno, Y.; Yoshida, M.; Yamamoto, H.; Boennemann, C.G.; Gussoni, E.; Denton, P.H.; Kyriakides, T.; Middelton, L.; Hentai, F.; Hamida, M.B.; Nonaka, I.; Vance, J.M.; Kunkel, L.M.; Ozawa, E. Mutations in the dystrophin-associated protein gammasarcoglycan in chromosome 13 muscular dystrophy. Science, 1995, 270, 819-822.
93. Nigro, V.; Moriera, E.; Piluso, G.; Vainzof, M.; Belsito, A.; Politano, L.; Puca, A.A.; Passos-Bueno, M.R. Zatz, M. The 5q autosomal recessive muscular dystrophy (LGMD 2F) is caused by a mutation in the δ-sarcoglycan gene. Nature Genet., 1996, 14, 195-198.
94. Guglieri, M.; Straub, V.; Bushby, K.; Lochmüller, H. Limb-girdle muscular dystrophies. Curr. Opin. Neurol., 2008, 21, 576-584.
95. Ohlendieck, K.; Matsumura, K.; Ionasescu, V.V.; Towbin, J.A.; Bosch, E.P.; Weinstein, S.L.; Sernett, S.W.; Campbell K.P. Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology, 1993, 43, 795-800.
96. Ohlendieck, K.; Campbell, K.P. Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J. Cell Biol., 1991, 115, 1685-1694.
97. Campbell, K.P.; Stull, J.T. Skeletal muscle basement membranesarcolemma-cytoskeleton interaction minireview series. J. Biol. Chem., 2003, 278, 12599-12600.
98. Yoon, J.H.; Johnson, E.; Xu, R.; Martin, L.T.; Martin, P.T.; Montanaro, F. Comparative Proteomic Profiling of Dystroglycan-Associated Proteins in Wild Type, mdx, and Galgt2 Transgenic Mouse Skeletal Muscle. J. Proteome Res., 2012, 11, 4413-4424.
99. Johnson, E.K.; Zhang, L.; Adams, M.E.; Phillips, A.; Freitas, M.A.; Froehner, S.C.; Green-Church, K.B.; Montanaro, F. Proteomic analysis reveals new cardiac-specific dystrophin-associated proteins. PLoS One, 2012, 7 (8), e43515.
100. rd; Gilchrist, A.; Howell, K.E.; Bergeron, J.J. Proteomics of organelles and large cellular structures. Nat. Rev. Mol. Cell Biol., 2005, 6, 702-714.
101. Gauthier, D.J.; Lazure, C. Complementary methods to assist subcellular fractionation in organellar proteomics. Expert Rev. Proteomics, 2008, 5, 603-617.
102. Lee, Y.H.; Tan, H.T.; Chung, M.C. Subcellular fractionation methods and strategies for proteomics. Proteomics, 2010, 10, 3935-3956.
103. Ohlendieck, K. Organelle proteomics in skeletal muscle biology. J. Integr. Omics, 2012, 2, 27-38.
104. Groen, A.J.; Lilley, K.S. Proteomics of total membranes and subcellular membranes. Expert Rev. Proteomics, 2010, 7, 867-878.
105. Staunton, L.; Ohlendieck, K. Mass spectrometric characterization of the sarcoplasmic reticulum from rabbit skeletal muscle by onmembrane digestion. Protein Pept. Lett., 2012, 19, 252-263.
106. Ge, Y.; Molloy, M.P.; Chamberlain, J.S.; Andrews, P.C. Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity. Proteomics, 2003, 3, 1895-1903.
107. Ge, Y.; Molloy, M.P.; Chamberlain, J.S.; Andrews, P.C. Differential expression of the skeletal muscle proteome in mdx mice at different ages. Electrophoresis, 2004, 25, 2576-2585.
108. 2+-binding proteins demonstrates decreased calsequestrin expression in dystrophic mouse skeletal muscle. Eur. J. Biochem., 2004, 271, 3943-3952.
109. Gardan-Salmon, D.; Dixon, J.M.; Lonergan, S.M.; Selsby, J.T. Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice. Eur. J. Appl. Physiol., 2011, 111, 2763-2773.
110. Carberry, S.; Zweyer, M.; Swandulla, D.; Ohlendieck, K. Profiling of age-related changes in the tibialis anterior muscle proteome of the mdx mouse model of dystrophinopathy. J. Biomed. Bioeng., 2012, 2012, 691641.
111. Carberry, S.; Brinkmeier, H.; Zhang, Y.; Winkler, C.K.; Ohlendieck, K. Comparative proteomic profiling of soleus, extensor digitorum longus, flexor digitorum brevis and interosseus muscles from the mdx mouse model of Duchenne muscular dystrophy. Int. J. Mol. Med. 2013, 32, 544-556.
112. Carberry, S.; Zweyer, M.; Swandulla, D.; Ohlendieck, K. Comparative proteomic analysis of the contractile protein-depleted fraction from normal versus dystrophic skeletal muscle. Anal. Biochem. 2013: In press.
113. Doran, P.; Dowling, P.; Donoghue, P.; Buffini, M.; Ohlendieck, K. Reduced expression of regucalcin in young and aged mdx diaphragm indicates abnormal cytosolic calcium handling in dystrophin-deficient muscle. Biochim. Biophys. Acta, 2006, 1764, 773-785.
114. Doran, P.; Martin, G.; Dowling, P.; Jockusch, H.; Ohlendieck, K. Proteome analysis of the dystrophin-deficient MDX diaphragm reveals a drastic increase in the heat shock protein cvHSP. Proteomics, 2006, 6, 4610-4621.
115. Doran, P.; Wilton, S.D.; Fletcher, S.; Ohlendieck, K. Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. Proteomics, 2009, 9, 671-685.
116. Carberry, S.; Zweyer, M.; Swandulla, D.; Ohlendieck, K. Proteomics reveals drastic increase of extracellular matrix proteins collagen and dermatopontin in the aged mdx diaphragm model of Duchenne muscular dystrophy. Int. J. Mol. Med., 2012, 30, 229-234.
117. Lewis, C.; Ohlendieck, K. Proteomic profiling of naturally protected extraocular muscles from the dystrophin-deficient mdx mouse. Biochem. Biophys. Res. Commun., 2010, 396, 1024-1029.
118. Gulston, M.K.; Rubtsov, D.V.; Atherton, H.J.; Clarke, K.; Davies, K.E.; Lilley, K.S.; Griffin, J.L. A combined metabolomic and proteomic investigation of the effects of a failure to express dystrophin in the mouse heart. J. Proteome Res., 2008, 7, 2069-2077.
119. Lewis, C.; Jockusch, H.; Ohlendieck, K. Proteomic profiling of the dystrophin-deficient MDX heart reveals drastically altered levels of key metabolic and contractile proteins. J. Biomed. Biotechnol., 2010, 2010, 648501.
120. Holland, A.; Dowling, P.; Zweyer, M.; Swandulla, D.; Henry, M.; Clynes, M.; Ohlendieck, K. Proteomic profiling of cardiomyopathic tissue from the aged mdx model of Duchenne muscular dystrophy reveals a drastic decrease in laminin, nidogen and annexin. Proteomics, 2013, 13, 2312-2323.
121. Guevel, L.; Lavoie, J.R.; Perez-Iratxeta, C.; Rouger, K.; Dubreil, L.; Feron, M.; Talon, S.; Brand, M.; Megeney, L.A. Quantitative proteomic analysis of dystrophic dog muscle. J. Proteome Res., 2011, 10, 2465-2478.
122. Luque-Garcia, J.L.; Zhou, G.; Sun, T.T.; Neubert, T.A. Use of nitrocellulose membranes for protein characterization by matrixassisted laser desorption/ionization mass spectrometry. Anal. Chem., 2006, 78, 5102-5108.
123. Luque-Garcia, J.L.; Neubert, T.A. On-membrane tryptic digestion of proteins for mass spectrometry analysis. Methods Mol. Biol., 2009, 536, 331-341.
124. Simspon, R.J. On-membrane proteolytic digestion of electroblotted proteins. Cold Spring Harb. Protoc., 2011, 2011, 995-997.
125. Ino, Y.; Hirano, H. Mass spectrometric characterization of proteins transferred from polyacrylamide gels to membrane filters. FEBS J., 2011, 278, 3807-3814.
126. Ohlendieck, K. On-Membrane Digestion Technology for Muscle Proteomics. J. Membr. Sep. Technol., 2013, 2, 1-12.
127. Krieger, C.C.; Bhasin, N.; Tewari, M.; Brown, A.E.; Safer, D.; Sweeney, H.L.; Discher, D.E. Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics. Cytoskeleton (Hoboken), 2010, 67, 796-807.
128. Brown, K.J.; Marathi, R.; Fiorillo, A.A.; Ciccimaro, E.F.; Sharma, S.; Rowlands, D.S.; Rayavarapu, S.; Nagaraju, K.; Hoffman, E.P.; Hathout, Y. Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. J. Bioanal. Biomed., 2012, Suppl 7, 1-16.
129. Rayavarapu, S.; Coley, W.; Cakir, E.; Jahnke, V.; Takeda, S.; Aoki, Y.; Grodish-Dressman, H.; Jaiswal, J.K.; Hoffman, E.P.; Brown, K.J.; Hathout. Y.; Nagaraju, K. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Mol. Cell. Proteomics, 2013, 12, 1061-1073.
130. Duguez, S.; Duddy, W.; Johnston, H.; Lainé, J.; Le Bihan, M.C.; Brown, K.J.; Bigot, A.; Hathout, Y.; Butler-Browne, G.; Partridge, T. Dystrophin deficiency leads to disturbance of LAMP1-vesicleassociated protein secretion. Cell. Mol. Life Sci., 2013, 70, 2159-2174.
131. Alagaratnam, S.; Mertens, B.J.; Dalebout, J.C.; Deelder, A.M.; van Ommen, G.J.; den Dunnen, J.T.; 't Hoen, P.A. Serum protein profiling in mice: identification of Factor XIIIa as a potential biomarker for muscular dystrophy. Proteomics, 2008, 8, 1552-1563.
132. Colussi, C.; Banfi, C.; Brioschi, M.; Tremoli, E.; Straino, S.; Spallotta, F.; Mai, A.; Rotili, D.; Capogrossi, M.C.; Gaetano, C. Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics Clin. Appl., 2010, 4, 71-83.
133. Guenet, J.L. Animal models of human genetic diseases: do they need to be faithful to be useful? Mol. Genet. Genomics, 2011, 286, 1-20.
134. Vainzof, M.; Ayub-Guerrieri, D.; Onofre, P.C.; Martins, P.C.; Lopes, V.F.; Zilberztajn, D.; Maia, L.S.; Sell, K.; Yamamoto, L.U. Animal models for genetic neuromuscular diseases. J. Mol. Neurosci., 2008, 34, 241-248.
135. Doran, P.; Gannon, J.; O'Connell, K.; Ohlendieck, K. Proteomic profiling of animal models mimicking skeletal muscle disorders. Proteomics Clin. Appl., 2007, 1, 1169-1184.
136. Banks, G.B.; Chamberlain, J.S. The value of mammalian models for Duchenne muscular dystrophy in developing therapeutic strategies. Curr. Top. Dev. Biol., 2008, 84, 431-453.
137. Bulfield, G.; Siller, W.G.; Wight, P.A.; Moore, K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci USA, 1984, 81, 1189-1192.
138. Deconinck, A.E.; Rafael, J.A.; Skinner, J.A.; Brown, S.C.; Potter, A.C.; Metzinger, L.; Watt, D.J.; Dickson, J.G.; Tinsley, J.M.; Davies, K.E. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell, 1997, 90, 717-727.
139. Durbeej, M.; Campbell, K.P. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr. Opin. Genet. Dev., 2002, 12, 349-361.
140. Kornegay, J.N.; Bogan, J.R.; Bogan, D.J.; Childers, M.K.; Li, J.; Nghiem, P.; Detwiler, D.A.; Larsen, C.A.; Grange, R.W.; Bhavaraju-Sanka, R.K.; Tou, S.; Keene, B.P.; Howard, J.F. Jr.; Wang, J.; Fan, Z.; Schatzberg, S.J.; Styner, M.A.; Flanigan, K.M.; Xiao, X.; Hoffman, E.P. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm. Genome., 2012, 23, 85-108.
141. Valentine, B.A.; Cooper, B.J.; de Lahunta, A.; O'Quinn, R.; Blue, J.T. Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J. Neurol. Sci., 1988, 88, 69-81.
142. Valentine, B.A.; Cooper, B.J.; Cummings, J.F.; deLahunta, A. Progressive muscular dystrophy in a golden retriever dog: light microscope and ultrastructural features at 4 and 8 months. Acta Neuropathol., 1986, 71, 301-310.
143. Cooper, B.J.; Winand, N.J.; Stedman, H.; Valentine, B.A.; Hoffman, E.P.; Kunkel, L.M.; Scott, M.O.; Fischbeck, K.H.; Kornegay, J.N.; Avery, R.J.; Williams, J.R.; Schmickel, R.D.; Sylvester, J.E. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature, 1988, 334, 154-156.
144. Gaiad, T.P.; Silva, M.B.; Silva, G.C.; Caromano, F.A.; Miglino, M.A.; Ambrósio, C.E. Physical therapy assessment tools to evaluate disease progression and phenotype variability in Golden Retriever muscular dystrophy. Res. Vet. Sci., 2011, 91, 188-193.
145. Kornegay, J.N.; Bogan, J.R.; Bogan, D.J.; Childers, M.K.; Grange, R.W. Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements. Methods Mol. Biol., 2011, 709, 105-123.
146. Sicinski, P.; Geng, Y.; Ryder-Cook, A.S.; Barnard, E.A.; Darlison, M.G.; Barnard, P.J. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science, 1989, 244, 1578-1580.
147. Partridge, T.A.; Morgan, J.E.; Coulton, G.R.; Hoffman, E.P.; Kunkel, L.M. Conversion of mdx myofibres from dystrophinnegative to-positive by injection of normal myoblasts. Nature, 1989, 337, 176-179.
148. Torres, L.F.; Duchen, L.W. The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and endplates. Brain, 1987, 110, 269-299.
149. Weller, B.; Karpati, G.; Carpenter, S. Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J. Neurol. Sci., 1990, 100, 9-13.
150. Lynch, G.S.; Rafael, J.A.; Chamberlain, J.S.; Faulkner, J.A. Contraction-induced injury to single permeabilized muscle fibers from mdx, transgenic mdx, and control mice. Am. J. Physiol. Cell. Physiol., 2000, 279, C1290-C1294.
151. Menke, A.; Jockusch, H. Decreased osmotic stability of dystrophinless muscle cells from the mdx mouse. Nature, 1991, 349, 69-71.
152. Turner, P.R.; Westwood, T.; Regen, C.M.; Steinhardt, R.A. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature, 1988, 335, 735-738.
153. + channels. Proc. Natl. Acad. Sci. USA, 2000, 97, 4950-4955.
154. Hopf, F.W.; Turner, P.R.; Steinhardt, R.A. Calcium misregulation and the pathogenesis of muscular dystrophy. Subcell. Biochem., 2007, 45, 429-464.
155. Allen, D.G.; Gervasio, O.L.; Yeung, E.W.; Whitehead, N.P. Calcium and the damage pathways in muscular dystrophy. Can. J. Physiol. Pharmacol., 2010, 88, 83-91.
156. Culligan, K.; Banville, N.; Dowling, P.; Ohlendieck, K. Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle. J. Appl. Physiol., 2002, 92, 435-445.
157. Dowling, P.; Doran, P.; Ohlendieck, K. Drastic reduction of sarcalumenin in Dp427 (dystrophin of 427 kDa)-deficient fibres indicates that abnormal calcium handling plays a key role in muscular dystrophy. Biochem. J., 2004, 379, 479-488.
158. Dowling, P.; Lohan, J.; Ohlendieck, K. Comparative analysis of Dp427-deficient mdx tissues shows that the milder dystrophic phenotype of extraocular and toe muscle fibres is associated with a persistent expression of beta-dystroglycan. Eur. J. Cell Biol., 2003, 82, 222-230.
159. Dowling, P.; Culligan, K.; Ohlendieck, K. Distal mdx muscle groups exhibiting up-regulation of utrophin and rescue of dystrophin-associated glycoproteins exemplify a protected phenotype in muscular dystrophy. Naturwissenschaften, 2002, 89, 75-78.
160. Marques, M.J.; Ferretti, R.; Vomero, V.U.; Minatel, E.; Neto, H.S. Intrinsic laryngeal muscles are spared from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy. Muscle Nerve, 2007, 35, 349-353.
161. Stedman, H.H.; Sweeney, H.L.; Shrager, J.B.; Maguire, H.C.; Panettieri, R.A.; Petrof, B.; Narusawa, M.; Leferovich, J.M.; Sladky, J.T.; Kell, A.M. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature, 1991, 352, 536-539.
162. Spurney, C.F.; Gordish-Dressman, H.; Guerron, A.D.; Sali, A.; Pandey, G.S.; Rawat, R.; Van Der Meulen, J.H.; Cha, H.J.; Pistilli, E.E.; Partridge, T.A.; Hoffman E.P.; Nagaraju, K. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve, 2009, 39, 591-602.
163. Wells, D.J.; Wells, K.E. Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD? Neuromuscul. Disord., 2002, 12, S11-S22.
164. Fairclough, R.J.; Perkins, K.J.; Davies, K.E. Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy. Curr. Gene Ther., 2012, 12, 206-244.
165. De Luca, A. Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview. Acta Myol., 2012, 31, 40-47.
166. Lefaucheur, J.P.; Pastoret, C.; Sebille, A. Phenotype of dystrophinopathy in old mdx mice. Anat. Rec., 1995, 242, 70-76.
167. 2+ homeostasis during fatigue. Exp. Physiol., 2010, 95, 641-656.
168. Pastoret, C.; Sebille, A. MDX mice show progressive weakness and muscle deterioration with age. J. Neurol. Sci., 1995, 129, 97-105.
169. Lynch, G.S.; Hinkle, R.T.; Chamberlain, J.S.; Brooks, S.V.; Faulkner, J.A. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J. Physiol., 2001, 535, 591-600.
170. Chamberlain, J.S.; Metzger, J.; Reyes, M.; Townsend, D.; Faulkner, J.A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J., 2007, 21, 2195-2204.
171. Irintchev, A.; Zweyer, M.; Wernig, A. Impaired functional and structural recovery after muscle injury in dystrophic mdx mice. Neuromuscul. Disord., 1997, 7, 117-125.
172. Mouisel, E.; Vignaud, A.; Hourde, C.; Butler-Browne, G.; Ferry, A. Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24-month-old) dystrophic mdx mice. Muscle Nerve, 2010, 41, 809-818.
173. Royer, L.; Ríos, E. Deconstructing calsequestrin. Complex buffering in the calcium store of skeletal muscle. J. Physiol., 2009, 587, 3101-3111.
174. Holland, A.; Ohlendieck, K. Proteomic profiling of the contractile apparatus from skeletal muscle. Expert Rev. Proteomics, 2013, 10, 239-257.
175. Selsby, J.T.; Morine, K.J.; Pendrak, K.; Barton, E.R.; Sweeney, H.L. Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS One, 2012, 7 (1), e30063.
176. Pedersen, B.K. Muscle as a secretory organ. Compr. Physiol., 2013, 3, 1337-1362.
177. Yáñez, M.; Gil-Longo, J.; Campos-Toimil, M. Calcium binding proteins. Adv. Exp. Med. Biol., 2012, 740, 461-482.
178. Yamaguchi, M. Role of regucalcin in calcium signaling. Life Sci., 2000, 66, 1769-1780.
179. 2+-ATPase activity in rat heart muscle. J. Cell. Biochem., 2002, 86, 184-193.
180. Yamaguchi, M. Regucalcin and cell regulation: role as a suppressor protein in signal transduction. Mol. Cell. Biochem., 2011, 353, 101-137.
181. Berchtold, M.W.; Brinkmeier, H.; Muntener, M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol. Rev., 2000, 80, 1215-1265.
182. Gehrig, S.M.; van der Poel, C.; Sayer, T.A.; Schertzer, J.D.; Henstridge, D.C.; Church, J.E.; Lamon, S.; Russell, A.P.; Davies, K.E.; Febbraio, M.A.; Lynch, G.S. Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature, 2012, 484, 394-398.
183. Krüger, J.; Kunert-Keil, C.; Bisping, F.; Brinkmeier, H. Transient receptor potential cation channels in normal and dystrophic mdx muscle. Neuromuscul. Disord., 2008, 18, 501-513.
184. Brinkmeier, H. TRP channels in skeletal muscle: gene expression, function and implications for disease. Adv. Exp. Med. Biol., 2011, 704, 749-758.
185. Gailly, P. TRP channels in normal and dystrophic skeletal muscle. Curr. Opin. Pharmacol., 2012, 12, 326-334.
186. Garrido, C.; Paul, C.; Seigneuric, R.; Kampinga, H.H. The small heat shock proteins family: the long forgotten chaperones. Int. J. Biochem. Cell Biol., 2012, 44, 1588-1592.
187. Brownell, S.E.; Becker, R.A.; Steinman, L. The protective and therapeutic function of small heat shock proteins in neurological diseases. Front. Immunol., 2012, 3, 74.
188. Minden, J.S.; Dowd, S.R.; Meyer, H.E.; Stühler, K. Difference gel electrophoresis. Electrophoresis, 2009, 30 (Suppl 1), S156-S161.
189. Lewis, C.; Doran, P.; Ohlendieck, K. Proteomic analysis of dystrophic muscle. Methods Mol. Biol., 2012, 798, 357-369.
190. Stamler, R.; Kappe, G.; Boelens, W.; Slingsby, C. Wrapping the alpha-crystallin domain fold in a chaperone assembly. J. Mol. Biol., 2005, 353, 68-79.
191. Golenhofen, N.; Perng, M.D.; Quinlan, R.A.; Drenckhahn, D. Comparison of the small heat shock proteins alphaB-crystallin, MKBP, HSP25, HSP20, and cvHSP in heart and skeletal muscle. Histochem. Cell Biol., 2004, 122, 415-425.
192. Ohlendieck, K. Proteomic identification of biomarkers of skeletal muscle disorders. Biomark. Med., 2013, 7, 169-186.
193. Ishizaki, M.; Suga, T.; Kimura, E.; Shiota, T.; Kawano, R.; Uchida, Y.; Uchino, K.; Yamashita, S.; Maeda, Y.; Uchino, M. Mdx respiratory impairment following fibrosis of the diaphragm. Neuromuscul. Disord., 2008, 18, 342-348.
194. Kragstrup, T.W.; Kjaer, M.; Mackey, A.L. Structural, biochemical, cellular, and functional changes in skeletal muscle extracellular matrix with aging. Scand. J. Med. Sci. Sports, 2011, 21, 749-757.
195. Goldspink, G.; Fernandes K.; Williams, P.E.; Wells, D.J. Agerelated changes in collagen gene expression in the muscles of mdx dystrophic and normal mice. Neuromuscul. Disord., 1994, 4, 183-191.
196. Graham, K.M.; Singh, R.; Millman, G.; Malnassy, G.; Gatti, F.; Bruemmer, K.; Stefanski, C.; Curtis, H.; Sesti, J.; Carlson, C.G. Excessive collagen accumulation in dystrophic (mdx) respiratory musculature is independent of enhanced activation of the NFkappaB pathway. J. Neurol. Sci., 2010, 294, 43-50.
197. Okamoto, O.; Fujiwara, S. Dermatopontin, a novel player in the biology of the extracellular matrix. Connect. Tissue Res., 2006, 47, 177-189.
198. Kato, A.; Okamoto, O.; Ishikawa, K.; Sumiyoshi, H.; Matsuo, N.; Yoshioka, H.; Nomizu, M.; Shimada, T.; Fujiwara, S. Dermatopontin interacts with fibronectin, promotes fibronectin fibril formation, and enhances cell adhesion. J. Biol. Chem., 2011, 286, 14861-14869.
199. Finsterer, J.; Stöllberger, C. The heart in human dystrophinopathies. Cardiology, 2003, 99, 1-19.
200. Russell, M.W.; Townsend, D.; Metzger, J.M. Cardiac involvement in the dystrophinopathies. J. Pediatr. Rehabil. Med., 2008, 1, 211-223.
201. Lohan, J.; Culligan, K.; Ohlendieck, K. Deficiency in Cardiac Dystrophin Affects the Abundance of the alpha-/beta-dystroglycan complex. J. Biomed. Biotechnol., 2005, 2005, 28-36.
202. 2+-binding proteins calsequestrin and sarcalumenin in dystrophindeficient cardiac muscle. Biochim. Biophys. Acta, 2004, 1689, 252-258.
203. 2+ influx into dystrophic mdx cardiomyocytes. Cell Calcium, 2009, 46, 114-121.
204. Bridges, L.R. The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX mice. J. Neurol. Sci., 1986, 72, 147-157.
205. Sapp, J.L.; Bobet, J.; Howlett, S.E. Contractile properties of myocardium are altered in dystrophin-deficient mdx mice. J. Neurol. Sci., 1996, 142, 17-24.
206. Bia, B.L.; Cassidy, P.J., Young, M.E.; Rafael, J.A.; Leighton, B.; Davies, K.E.; Radda, G.K.; Clarke, K. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J. Mol. Cell. Cardiol., 1999, 31, 1857-1862.
207. Spurney, C.F.; Knoblach, S.; Pistilli, E.E.; Nagaraju, K.; Martin, G.R.; Hoffman, E.P. Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul. Disord., 2008, 18, 371-381.
208. Stalnaker, S.H.; Aoki, K.; Lim, J.M.; Porterfield, M.; Liu, M.; Satz, J.S.; Buskirk, S.; Xiong, Y.; Zhang, P.; Campbell, K.P.; Hu, H.; Live, D.; Tiemeyer, M.; Wells, L. Glycomic analyses of mouse models of congenital muscular dystrophy. J. Biol. Chem., 2011, 286, 21180-21190.
209. Harrison, R.; Hitchen, P.G.; Panico, M.; Morris, H.R.; Mekhaiel, D.; Pleass, R.J.; Dell, A.; Hewitt, J.E.; Haslam, S.M. Glycoproteomic characterization of recombinant mouse α-dystroglycan. Aberrant glycosylation of the protein has been linked to various forms of congenital muscular dystrophy. Glycobiology, 2012, 22, 662-675.
210. Frigeri, A.; Nicchia, G.P.; Verbavatz, J.M.; Valenti, G.; Svelto, M. Expression of aquaporin-4 in fast-twitch fibers of mammalian skeletal muscle. J. Clin. Invest., 1998, 102, 695-703.
211. Adams, M.E.; Mueller, H.A.; Froehner, S.C. In vivo requirement of the alpha-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. J. Cell Biol., 2001, 155, 113-122.
212. Liu, J.W.; Wakayama, Y.; Inoue, M.; Shibuya, S.; Kojima, H.; Jimi, T.; Oniki, H. Immunocytochemical studies of aquaporin 4 in the skeletal muscle of mdx mouse. J. Neurol. Sci., 1999, 164, 24-28.
213. Frigeri, A.; Nicchia, G.P.; Nico, B.; Quondamatteo, F.; Herken, R.; Roncali, L.; Svelto, M. Aquaporin-4 deficiency in skeletal muscle and brain of dystrophic mdx mice. FASEB J., 2001, 15, 90-98.
214. Hara, H.; Wakayama, Y.; Kojima, H.; Inoue, M.; Jimi, T.; Iijima, S.; Masaki H. Aquaporin 4 Expression in the mdx Mouse Diaphragm. Acta Histochem. Cytochem., 2011, 44, 175-182.
215. Basco, D.; Nicchia, G.P.; D'Alessandro, A.; Zolla, L.; Svelto, M.; Frigeri, A. Absence of aquaporin-4 in skeletal muscle alters proteins involved in bioenergetic pathways and calcium handling. PLoS One, 2011, 6 (4), e19225.
216. Mouly, V.; Aamiri, A.; Périé, S.; Mamchaoui, K.; Barani, A.; Bigot, A.; Bouazza, B.; François, V.; Furling, D.; Jacquemin, V.; Negroni, E.; Riederer, I.; Vignaud, A.; St Guily, J.L.; Butler-Browne, G.S. Myoblast transfer therapy: is there any light at the end of the tunnel? Acta Myol., 2005, 24, 128-133.
217. Farini, A.; Razini, P.; Erratico, S.; Torrente, Y.; Meregalli, M. Cell based therapy for Duchenne muscular dystrophy. J. Cell Physiol., 2009, 221, 526-534.
218. Meregalli, M.; Farini, A.; Parolini, D.; Maciotta, S.; Torrente, Y. Stem cell therapies to treat muscular dystrophy: progress to date. BioDrugs, 2010, 24, 237-247.
219. Hoffman, E.P.; Bronson, A.; Levin, A.A.; Takeda, S.; Yokota, T.; Baudy, A.R.; Connor, E.M. Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am. J. Pathol., 2011, 179, 12-22.
220. Seto, J.T.; Ramos, J.N.; Muir, L.; Chamberlain, J.S.; Odom, G.L. Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors. Curr. Gene Ther., 2012, 12, 139-151.
221. Verhaart, I.E.; Aartsma-Rus, A. Gene therapy for Duchenne muscular dystrophy. Curr. Opin. Neurol., 2012, 25, 588-596.
222. Mitrpant, C.; Fletcher, S.; Wilton, S.D. Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping. Curr. Mol. Pharmacol., 2009, 2, 110-121.
223. Lu, Q.L.; Yokota, T.; Takeda, S.; Garcia, L.; Muntoni, F.; Partridge, T. The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy. Mol. Ther., 2011, 19, 9-15.
224. Aartsma-Rus, A. Overview on DMD exon skipping. Methods Mol. Biol., 2012, 867, 97-116.
225. Arechavala-Gomeza, V.; Anthony, K.; Morgan, J.; Muntoni, F. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges. Curr. Gene Ther., 2012, 12, 152-160.
226. Aoki, Y.; Yokota, T.; Nagata, T.; Nakamura, A.; Tanihata, J.; Saito, T.; Duguez, S.M.; Nagaraju, K.; Hoffman, E.P.; Partridge. T.; Takeda, S. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci. USA, 2012, 109, 13763-13768.
227. Yokota, T.; Nakamura, A.; Nagata, T.; Saito, T.; Kobayashi, M.; Aoki, Y.; Echigoya, Y.; Partridge, T.A.; Hoffman, E.P.; Takeda, S. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther., 2012, 22, 306-315.
228. Kinali, M.; Arechavala-Gomeza, V.; Feng, L.; Cirak, S.; Hunt, D.; Adkin, C.; Guglieri, M.; Ashton, E.; Abbs, S.; Nihoyannopoulos, P.; Garralda, M.E.; Rutherford, M.; McCulley, C.; Popplewell, L.; Graham, I.R.; Dickson, G.; Wood, M.J.; Wells, D.J.; Wilton, S.D.; Kole, R.; Straub, V.; Bushby, K.; Sewry, C.; Morgan, J.E.; Muntoni, F. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-ofconcept study. Lancet Neurol., 2009, 8, 918-928.
229. Goemans, N.M.; Tulinius, M.; van den Akker, J.T.; Burm, B.E.; Ekhart, P.F.; Heuvelmans, N.; Holling, T.; Janson, A.A.; Platenburg, G.J.; Sipkens, J.A.; Sitsen, J.M.; Aartsma-Rus, A.; van Ommen, G.J.; Buyse, G.; Darin, N.; Verschuuren, J.J.; Campion, G.V.; de Kimpe, S.J.; van Deutekom, J.C. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med., 2011, 364, 1513-1522.
230. Cirak, S.; Arechavala-Gomeza, V.; Guglieri, M.; Feng, L.; Torelli, S.; Anthony, K.; Abbs, S.; Garralda, M.E.; Bourke, J.; Wells, D.J.; Dickson, G.; Wood, M.J.; Wilton, S.D.; Straub. V.; Kole, R.; Shrewsbury, S.B.; Sewry, C.; Morgan, J.E.; Bushby, K.; Muntoni, F. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, doseescalation study. Lancet, 2011, 378, 595-605.
231. Koo, T.; Wood, M.J. Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum. Gene Ther., 2013, 24, 479-488.